SEC Form 4 · accession 0001553878-15-000026

ALNYLAM PHARMACEUTICALS, INC. · ALNY

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — VP, Finance and Treasurer

Period of report

Jun 1, 2015

Accepted (ET)

Jun 3, 2015 · 4:33 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001178670

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Jun 1, 2015	M	1,563	$10.98	A	1,563	D
Common Stock	Jun 1, 2015	M	37	$63.00	A	1,600	D
Common Stock	Jun 1, 2015	M	1,524	$63.00	A	3,124	D
Common Stock	Jun 1, 2015	M	1,667	$63.00	A	4,791	D
Common Stock^F2	Jun 1, 2015	S	760	$130.3921	D	4,031	D
Common Stock^F3	Jun 1, 2015	S	1,767	$131.5636	D	2,264	D
Common Stock^F4	Jun 1, 2015	S	2,064	$132.4862	D	200	D
Common Stock^F5	Jun 1, 2015	S	200	$133.12	D	0	D
Common Stock^F6	holding	—	—		—	2,007	I	By Managed Account

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Performance-Based Stock Option (Right to Buy)^F7	$63.00	Jun 1, 2015	M	1,667	D	—	Dec 18, 2023	Common Stock	1,667	0	D
Stock Option (Right to Buy)^F8	$63.00	Jun 1, 2015	M	37	D	—	Dec 18, 2023	Common Stock	37	4,963	D
Stock Option (Right to Buy)^F8	$63.00	Jun 1, 2015	M	1,524	D	—	Dec 18, 2023	Common Stock	1,524	3,439	D
Stock Option (Right to Buy)^F8	$10.98	Jun 1, 2015	M	1,563	D	—	Feb 28, 2021	Common Stock	1,563	0	D

F1The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2015.
F2Sale prices ranged from $130.02 to $130.89.
F3Sale prices ranged from $131.03 to $131.935.
F4Sale prices ranged from $132.06 to $132.98.
F5Sale prices ranged from $133.10 to $133.14.
F6The reporting person owns 2,007 shares of ALNY common stock under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.
F7On December 18, 2013, the reporting person was granted a performance based stock option to purchase shares of ALNY Common Stock. One-third of the shares subject to the option will vest upon the achievement of each of three specific clinical development and regulatory events, as approved by the compensation committee of the Company. Effective December 12, 2014, the compensation committee of the Company determined the first performance criteria had been met and the option was vested as to one-third of the shares.
F8The stock option vests as to 25% of the shares on the first anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three-month period thereafter.